Skip to main
AORT

Artivion (AORT) Stock Forecast & Price Target

Artivion (AORT) Analyst Ratings

Based on 6 analyst ratings
Strong Buy
Strong Buy 67%
Buy 33%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Artivion is positioned to experience strong long-term growth in the range of 10%-14%, driven by the opportunities for their recent PMAs (AMDS and Nexus) and their pipeline of products, including Arcevo and product line extensions of Nexus. The company's main risks include potential tariffs and exposure to corruption as it continues to expand globally, and potential regulatory challenges surrounding their tissue preservation services and sterilization methods. However, we remain positive on the company's outlook and believe its current valuation presents an attractive buying opportunity.

Bears say

Artivion is facing challenges in the Medical Devices segment due to delays in FDA approval and financial hurdles for their products. This has resulted in a reduction in revenue guidance for 2026. Additionally, the use of free cash flow for future earn-outs and debt repayment may limit the company's ability to generate profits. The potential launch of NEXUS in 2027 could provide a positive impact, but the company may still face challenges in terms of onboarding new accounts and dealing with the financial commitment required for product usage.

Artivion (AORT) has been analyzed by 6 analysts, with a consensus rating of Strong Buy. 67% of analysts recommend a Strong Buy, 33% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Artivion and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Artivion (AORT) Forecast

Analysts have given Artivion (AORT) a Strong Buy based on their latest research and market trends.

According to 6 analysts, Artivion (AORT) has a Strong Buy consensus rating as of Sep 12, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $44.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $44.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Artivion (AORT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.